Sunitinib
From OncoWiki
Jump to navigationJump to search
Regimen
- Sunitinib (Sutent) 50 mg po qd x 4 wks, repeat after 2 wks rest
Approved by FDA on 2/2/07
- Sutent is a targeted therapy and is a receptor protein-tyrosine kinase inhibitor. It inhibits the actions of vascular endothelial growth factor (VEGF) and is an angiogenesis inhibitor.
- Sutent Use and Sutent Side Effects Information
References
Motzer RJ et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516